-
A–E
Immunohistochemistry stainings with antibodies directed against CD31 (A) and Ang‐2 (B) in treatment‐naive GBM, post‐radiochemotherapy (S/RTx/CTx), and post‐radiochemotherapy + bevacizumab (S/RTx/CTx/Bev) therapy are displayed. Quantitative analyses of microvessel densities and Ang‐2+ vessels are shown in (C) and (D). The ratio of Ang‐2+ versus CD31+ vessels was determined in (E). Scale bars: 200 μm (A), 100 μm (B).
-
F
Western Blot and corresponding quantification of CD31 and Ang‐2 in control and aflibercept‐treated mice (n = 5 each).
-
G–I
CAIX staining of treatment‐naive GBM and S/RTx/CTx/Bev patients. Analyses of hypoxic (CAIX
+) area with regard to the whole tumor in human GBM (H). Tumor‐infiltrating lymphocytes (CD8/CD3) in human patients (I). Scale bar: 100 μm.
Data information: Kruskal–Wallis (C–E, H–I). *
P <
0.05, **
P <
0.01, ***
P <
0.005; treatment‐naive GBM
n =
26, S/RTx/CTx
n =
7, S/RTx/CTx/Bev
n =
29;
t‐test (F); data are mean ± SEM.
